Peptides that target central nervous system pathways involved in sexual arousal, desire, and performance through melanocortin receptor activation.
LibidoArousalMelanocortinPerformance
Sexual function peptide research focuses on compounds that act through central nervous system pathways rather than peripheral vascular mechanisms (like PDE5 inhibitors such as sildenafil). The melanocortin system, particularly MC3R and MC4R receptors in the hypothalamus, plays a critical role in sexual arousal and desire. PT-141 (bremelanotide) represents the most clinically validated peptide in this category, with FDA approval for hypoactive sexual desire disorder. Kisspeptin-10 adds a hormonal dimension through its effects on the reproductive axis and limbic activation.
FDA-approved melanocortin receptor agonist (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. PT-141 acts centrally on MC3R and MC4R in the hypothalamus to enhance sexual arousal and desire, working through an entirely different pathway than PDE5 inhibitors.
Neuropeptide that activates the HPG axis for testosterone production and has been shown to enhance brain processing of sexual and emotional stimuli in clinical studies. Kisspeptin activates limbic brain regions associated with attraction and pair bonding.
◆ ◆ ◆
Frequently Asked Questions.
PT-141 (bremelanotide) acts on melanocortin receptors in the brain to enhance desire and arousal centrally. Viagra (sildenafil) inhibits PDE5 to increase blood flow peripherally. PT-141 targets the desire component of sexual function, while PDE5 inhibitors target the vascular/mechanical component. They work through entirely different pathways.
PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. However, research studies have also demonstrated efficacy in men with erectile dysfunction, including cases unresponsive to PDE5 inhibitors. Male clinical research exists but has not resulted in a male-specific FDA approval.
The most common side effects include nausea (40%), flushing, headache, and injection site reactions. Nausea is typically transient and dose-related. PT-141 can cause transient increases in blood pressure and is contraindicated in uncontrolled hypertension.
Research Disclaimer: Content on PowerPeptides.co is for informational and research purposes only. It is not medical advice. Peptides discussed are research compounds unless explicitly noted as FDA-approved. Always consult a licensed healthcare provider before beginning any peptide protocol. Full Disclaimer | Affiliate Disclosure